Viral MIP-II Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: MIP-II

Human herpesvirus-8 (HHV‑8)/Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gamma  herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus. HHV‑8 is etiologically linked to Kaposi’s sarcoma and a B-cell lymphoma known as primary effusion lymphoma. HHV‑8 has been shown to encode a variety of immunomodulatory proteins which were apparently pirated from cellular genes by the virus. Three chemokine-like proteins, vMIP-I, vMIP-II and vMIP-III have been found to be encoded within the HHV‑8 genome.

Viral MIP-II cDNA encodes a 94 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide that is cleaved to yield a 71 aa residue mature protein. Among human chemokines, vMIP-II is most closely related to MIP-1 alpha, sharing approximately 41% amino acid sequence identity. At the amino acid sequence level, vMIP-I and vMIP-II also share 48% identity. vMIP-I and vMIP-II are more closely related to one another phylogenetically than to other human chemokines, suggesting that they may have arisen by gene duplication within the virus rather than by two independent gene aquisitions. vMIP-II binds to the CCR-3 chemokine receptor through which eotaxin and other beta chemokines activate eosinophils. vMIP-II has been shown to activate and chemoattract human eosinphils. Both vMIP-I and vMIP-II have been shown to partially block HIV infection of peripheral blood mononuclear cells. vMIP-I and vMIP-II have also been found to be highly angiogenic in the chorioallantoic assay, suggesting that they may be partially responsible for the marked vascularity seen in KSHV-associated tumors.

Product Datasheets

Related Research Areas

• CC Chemokines and Receptors
• Chemokines and Receptors in Angiogenesis
• Infectious Diseases